Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

Journal of Bone and Mineral Research

Volumn 31, Issue 10, 2016, Pages 1827-1834

  Zebaze, Roger ^a   Libanati, Cesar ^b   McClung, Michael R ^c   Zanchetta, José R ^d   Kendler, David L ^e   Høiseth, Arne ^f   Wang, Andrea ^b   Ghasem Zadeh, Ali ^a   Seeman, Ego ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AMGEN INC   (United States)

^c OREGON OSTEOPOROSIS CENTER   (United States)

^d Instituto de Investigaciones Metabolicas   (Argentina)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Curato Røntgen   (Norway)

Author keywords

ANALYSIS QUANTIFICATION OF BONE OTHER; DISEASES OF THE BONE OSTEOPOROSIS; PRACTICE FRACTURE PREVENTION; THERAPEUTICS OTHER

Indexed keywords

CALCIUM; DENOSUMAB; PLACEBO; VITAMIN D;

AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL SHAFT; FINITE ELEMENT ANALYSIS; FOLLOW UP; HUMAN; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; POROSITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; FEMORAL NECK; HIP FRACTURE; MENOPAUSE; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; DENOSUMAB; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP FRACTURES; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POROSITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84971467950     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2855     Document Type: Article

References (33)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007; 22(3):465–75.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726–33.
3. Office of the Surgeon General (US). Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Office of the Surgeon General; 2004.
4. Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21):2250–61.
5. Høiseth A, Alho A, Husby T. Femoral cortical/cancellous bone related to age. Acta Radiol. 1990; 31(6):626–7.
6. Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ 3rd. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981; 67(2):328–35.
7. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375(9727):1729–36.
8. Schaffler MB, Burr DB. Stiffness of compact bone: effects of porosity and density. J Biomech. 1988; 21(1):13–6.
9. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology (Oxford). 2008; 47 Suppl 4:iv2–8.
10. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756–65.
11. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009; 24(2):182–95.
12. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11(5):401–19.
13. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49(2):151–61.
14. Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014; 59:173–9.
15. Genant HK, Libanati C, Engelke K, et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 2013; 56(2):482–8.
16. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23(12):1974–82.
17. Keaveny TM, Kopperdahl DL, Melton LJ 3rd, et al. Age-dependence of femoral strength in white women and men. J Bone Miner Res. 2010; 25(5):994–1001.
18. Poole KE, Treece GM, Gee AH, et al. Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res. 2015; 30(1):46–54.
19. Zysset PK, Dall'ara E, Varga P, Pahr DH. Finite element analysis for prediction of bone strength. Bonekey Rep. 2013; 2:386.
20. McClung MR, Zanchetta JR, Høiseth A, et al. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom. 2013; 16(2):250–6.
21. Zebaze R, Ghasem-Zadeh A, Mbala A, Seeman E. A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone. 2013; 54(1):8–20.
22. Ahmed LA, Shigdel R, Joakimsen RM, et al. Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures. Osteoporos Int. 2015; 26(8):2137–46.
23. Shigdel R, Osima M, Ahmed LA, et al. Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures. Bone. 2015; 81:1–6.
24. Keaveny TM, McClung MR, Genant HK, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014; 29(1):158–65.
25. Matheny JB, Slyfield CR, Tkachenko EV, et al. Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone. 2013; 57(1):277–83.
26. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206(983):489–90.
27. Parfitt AM. Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego, CA: Academic Press; 1996. p. 315–39.
28. Baron R. Importance of the intermediate phase between resorption and formation in the understanding and measurement of the bone remodeling sequence. In: Meunier PJ, editor. Bone histomorphometry. Paris: Laboratory Armour-Montagu; 1977. p. 179–83.
29. Frost HM. The skeletal intermediary organization: a synthesis. In: Pack WA, editor. Bone and mineral research 3. Amsterdam: Elsevier; 1985. p. 49–107.
30. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB. Aging of microstructural compartments in human compact bone. J Bone Miner Res. 2003; 18(6):1012–9.
31. Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49(2):162–73.
32. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010; 25(12):2558–71.
33. Ruffoni D, Fratzl P, Roschger P, Klaushofer K, Weinkamer R. The bone mineralization density distribution as a fingerprint of the mineralization process. Bone. 2007; 40(5):1308–19.